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Abstract
Background: Patients affected by progressive long-term neurological conditions might benefit from specialist
palliative care involvement. However, little is known on how neurology and specialist palliative care services
interact. This study aimed to map the current level of connections and integration between these services.
Methods: The mapping exercise was conducted in eight centres with neurology and palliative care services in the
United Kingdom. The data were provided by the respective neurology and specialist palliative care teams.
Questions focused on: i) catchment and population served; ii) service provision and staffing; iii) integration and
relationships.
Results: Centres varied in size of catchment areas (39-5,840 square miles) and population served (142,000-3,500,000).
Neurology and specialist palliative care were often not co-terminus. Service provisions for neurology and specialist
palliative care were also varied. For example, neurology services varied in the number and type of provided clinics and
palliative care services in the settings they work in. Integration was most developed in Motor Neuron Disease (MND),
e.g., joint meetings were often held, followed by Parkinsonism (made up of Parkinson’s Disease (PD), Multiple-System
Atrophy (MSA) and Progressive Supranuclear Palsy (PSP), with integration being more developed for MSA and
PSP) and least in Multiple Sclerosis (MS), e.g., most sites had no formal links. The number of neurology
patients per annum receiving specialist palliative care reflected these differences in integration (range: 9–88
MND, 3–25 Parkinsonism, and 0–5 MS).
Conclusions: This mapping exercise showed heterogeneity in service provision and integration between
neurology and specialist palliative care services, which varied not only between sites but also between
diseases. This highlights the need and opportunities for improved models of integration, which should be
rigorously tested for effectiveness.
Keywords: Neurology, Palliative care, Integrated care, Intervention, Mapping, End of life care, Terminal care,
Hospice, Home
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Background
Patients severely affected by progressive long-term
neurological conditions such as Multiple Sclerosis (MS),
Parkinson’s Disease (PD), Multiple-System Atrophy (MSA),
Progressive Supranuclear Palsy (PSP) (grouped together
as Parkinsonism), and Motor Neuron Disease (MND)
have unmet physical and psychological needs [1, 2],
similar to cancer patients [3] and experience problems
in coordination and continuity of care [4]. For example,
Parkinsonism patients experience on average more than
10 symptoms [5], which also include many non-motor
symptoms such as fatigue or psychological problems
[6]. These diseases also pose significant demands on
caregivers [7] who experience unmet needs [8].
Such complex, person-focused needs highlight the
potential for specialist palliative care involvement. This
has been recommended by the National Service Frame-
work for long term conditions for patients with long-term
neurological conditions early in the disease trajectory
[9]. Palliative care aims to deliver physical, psycho-
logical, emotional and spiritual care for patients with
progressive and serious illness, and their caregivers.
Despite this recommendation, patients severely affected
by neurological conditions often have limited access to
specialist palliative care services [10].
A main factor limiting palliative care involvement in
long term neurological conditions (LTNC) is the lack of
evidence-based knowledge on how this should be done.
So far, only a few models of integration between ne-
urology and palliative care have been described. One
Canadian palliative care service for patients with PD
[11] seems to improve patients’ symptoms over
3 months [12]. However, exactly how and when patients
are referred and the exact intervention format is un-
clear. In the UK, an integrated model in advanced MS
showed improvements in patients’ symptoms, caregiver
burden and costs [13, 14] after a 6-week intervention in
which palliative care and neurology worked closely to-
gether. However, whether this model would also be
possible and successful in other neurological conditions
and settings is unclear.
To develop and test better integrated models of
care between neurology and specialist palliative care
for patients with several progressive long-term neuro-
logical conditions (such as MS, PD, MSA, PSP, and
MND) across different care settings and services, it is
needed to explore the existing type and level of inte-
gration. Such insight is still largely missing. Therefore,
this study aimed to map the integration between
neurology and specialist palliative care services in dif-
ferent centres within the UK. This is an important
first step to develop and test new models of care,
which could ultimately lead to better care and im-
proved patients’ outcomes.
Methods
Design
A mapping exercise integrating data from a workshop,
e-mail survey of centres and analysis of routine data.
Setting
England and Wales, 8 sites purposively selected as they
were larger centres with both neurology and specialist
palliative care in the same catchment area and were
potentially interested in taking part in a future trial of
neurology and specialist palliative care. The eight sites
included different geographical areas of the UK (ranging
from South-East to North-West) and represented both
rural and urban areas. Within the sites we had the broad
range of services offered in the UK, including voluntary
and NHS hospices, hospital and community based
palliative care multidisciplinary teams, as well as ter-
tiary and secondary neurological services, incorporat-
ing multidisciplinary teams for MS, Parkinsonism
and MND.
Informants
Both neurology and palliative care providers from the
different centres completed the mapping document.
Procedures
1. We hosted a workshop for the sites to explore issues
that were to be subsequently considered in the
mapping exercise. This identified preliminary
similarities and variations and hence informed the
questions asked in the mapping exercise.
2. The mapping questions were developed by IH, WG
and LV with input from lead neurology and
palliative care providers. The questions covered: i)
the catchment area of the neurology and specialist
palliative care services, population served and
numbers of patients seen; ii) services and staffing;
and iii) integration and relationships between
neurology and specialist palliative care (e.g., joint
clinics) (see Additional file 1 for the mapping
questions for the neurology and specialist palliative
care teams).
3. The mapping questions were sent via email to
informants for each site. Key informants from all
sites were contacted, who then liaised with
additional members of the team to gather all
information. Informants completed information via
e-mail. We made use of several reminders and
follow-up emails and telephone contacts in the
period between June-November 2014 to obtain all
information.
4. Received information was checked (by DF or LV)
and if needed additional information was requested
van Vliet et al. BMC Neurology  (2016) 16:63 Page 2 of 7
via e-mail or telephone. It sometimes proved difficult
to obtain certain information, such as specific
catchment areas or information on the specific
number of patients seen (especially broken down to
neurological conditions). Ultimately, almost all
necessary information was retrieved. Some
demographic information was retrieved from
governmental published information, e.g., the 2011
census provided by the Office for National
Statistics.1
Analysis
Data were transferred into tables to facilitate comparison
between sites.
Results
Catchment areas, population served and patients seen
annually
Neurology
Heterogeneity in catchment area, population served and
patients seen annually was found across the eight sites.
Catchment areas (39-6,525 square miles) and population
numbers (142,000-3,500,000) varied. MS services saw
the most patients per year (<500- > 5000), followed by
Parkinsonism (<150 appointments per year- > 1550
patients a year) while MND patients were seen least
(10- > 400). See Table 1 for a summary of results and
Additional file 2 for in-depth details for each site.
Palliative care
Heterogeneity in catchment area, population served
and patients seen annually was found across the eight
sites. The catchment areas were not co-terminus
(overlapping) with neurology services for six of the
eight sites. Catchment areas (39- 1,008 square miles)
and estimated population numbers (235,000-1,398,000)
varied. Of the 550-2,298 patients that were annually
seen, only a small subset were neurology patients;
varying between 20 and 100. Seven of the eight sites
saw less than 50 neurology patients per year (Table 1
and Additional file 2)
Neurology service provision
Among the eight sites, the provided services (and staff )
were disease specific. For MS, frequent clinics were
held in almost all sites. This was sometimes supple-
mented by nurse-led telephone helplines or home visits.
Nurses and neurology consultants made up most of the
teams, often supplemented by physiotherapists and
sometimes other professionals such as a psychologist
(detailed data about staff not shown). For MND,
services included clinics (although less often than the
MS clinics) with often a focus on holistic, multi-
Table 1 Neurology and specialist palliative care service information in the eight centres in the UK
Characteristics Condition Neurology service Palliative care service
Catchment area
(square miles)
MS Range: 39– 5,840 Range: 39 – 1,008
MND Range: 39 – 5,840
Parkinsonism Range: 39 – 6,525
Population of catchment
area (number)
MS Range: 142,000 – 3,500,000 Range: 235,000 – 1,398,000
MND Range: 142,000 – 3,500,000
Parkinsonism Range: 300,000 – 3,500,000
Number of patients
seen annually
MS Range: 457 – 5,018
(3510 outpatient + 1508 inpatient)
Range: 0 - 5
MND Range: 10 - 400 Range: 9/12 - 88
Parkinsonism Range: 148 (appointments per year) – 1,558
(161 inpatients, 1397 outpatients)
Range: 3 - 25
Total – not disease
specific
Range: 550 – 2,298
Service provided MS Frequent clinics. Some sites nurse-led telephone
helplines and home visits.
Various setting; hospital, community and hospice.
Most across settings
MND Clinics (focus on holistic, multi-professional
service).
Parkinsonism Clinics (inclination to work multi-professionally).
Some links to community
Integration of the
two services
MS Limited – most sites no joint visits, or formal links. Some informal relations, few sites joint clinics.
MND Joined - most sites joint visits or other (formal) relationships
Parkinsonism Limited to Mixed – most sites no joint visits or other formal relationships.
Disease dependent – best for MSA/PSP
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professional service. The MND teams were multidis-
plinary; e.g., occupational therapists, speech and lan-
guage therapists were often present, supplemented by a
variety of providers such as dieticians and care coordi-
nators. Some sites, however, only comprised of a small
group, such as a consultant and nurse. Lastly, for
Parkinsonism, again clinics were held at almost all
sites. There also seemed to be an inclination to work
multi-disciplinary (e.g., at one site there was multi-
disciplinary team meeting (MDT) with input from
care of the elderly) with some links to the community
(e.g., telephone support or a community based nurse).
However, overall in Parkinsonism the consultants and
nurses formed the clinical teams. Sometimes other
professionals, e.g., physiotherapist and speech therap-
ist were involved (Table 1 & Additional file 3).
Specialist palliative care service provision
The specialist palliative care services varied with re-
spect to the settings they work in. Most sites worked
across different settings, namely (a combination of )
hospital, hospice and the community. However, some
sites worked solely in one setting, e.g., hospital, com-
munity or hospice.
The staff employed at each of the sites (data not
shown) reflects the multidisciplinary philosophy of pal-
liative care, although consultants (including registrars)
and (specialist) nurses formed the majority of the work-
force. Social workers and occupational therapists were
part of the team in a majority of sites or could be drawn
upon. Other Allied Health Professionals such as a chap-
lain or counsellor were sometimes part of the core team.
The most diverse teams were located in hospices (e.g.,
one site employed a creative therapist) (Table 1 and
Additional file 4).
Integration of specialist palliative care and neurology
The integration between neurology and palliative care
teams varied between sites, but more clearly between
diseases. For MS the integration seemed rather limited.
Most sites had no joint visits or formal links. Two
sites broke this trend. In one site an 8-weekly MDT
meeting was held in which both MS and Palliative
care teams participated while at another a 3-monthly
complex problem clinic was held with Palliative Care
attendance.
For MND a different picture emerged of stronger
integration. Most sites had either joint clinics or
Palliative Care attending MDT meetings. At one site
all MND patients were invited to clinics at the hos-
pice while at another site all patients received a pal-
liative care assessment. Good informal links, with the
MND and palliative care nurses sharing an office, was
reported in one site with no joint visits. The least
integrated site had no joint clinics and referrals based
on needs.
Lastly, in Parkinsonism the integration seemed mixed.
Around half of the sites had no joint clinics or formal
relationships. Other sites had clinics or MDTs 2- to
3-monthly with one site having palliative care attend-
ance at weekly clinics. There also seems to be a dif-
ference between the subsets of diseases. MSA and
PSP patients were more often considered for palliative
care input at one site, while another site hosted a
PSP forum (but was not involved) and a last site had
a virtual round, palliative MDT meeting and joint
clinic 2-monthly for PSP/MSA patients (see Table 1
and Additional file 4).
Discussion
This mapping exercise showed wide variation across
centers in the UK regarding the neurology and specialist
palliative care services available and their level of inte-
gration. The eight sites ranged in geographical location
and catchment area, which was (non-linearly) reflected
in the number of patients seen within each site. Explor-
ation of the selected sites and the service provision
informs understanding on the current integration
between neurology and specialist palliative care, and
the need and opportunities for better integrated models
of care.
Overall, our results indicate that in the UK neurology
patients do not often access specialist palliative care, al-
though differences between disease groups are present.
This might be problematic, as it has been estimated
that between 63 and 82 % of all deaths would have
needed palliative care involvement [15]. Moreover,
neurology patients experience palliative care symptoms
such as pain, breathlessness, worry and fatigue [3], are
at the end of life regularly hospitalised [15] and it is not
uncommon that they die here (quality issues with death
registration data should be taken into account) [16]. Of
course, neurological diseases are heterogeneous and in
our sample, MS patients were seen least by specialist
palliative care, followed by Parkinsonism (with more in-
volvement for MSA and PSP then PD) and MND. This
was reflected in organizational differences; the integra-
tion between specialist palliative care and neurology
was least developed in MS but joint clinics or MDT
meetings took place in most sites for MND patients.
Our data suggest that variations in specialist palliative
care involvement are related to disease trajectory rather
than disease prevalence. MND generally has a poor
prognosis of a few years. This is followed by MSA
and PSP, although there are subgroups in MSA such
as the parkinsonian variant which may have a progno-
sis of 15 years. Despite the fact that PD and MS
might not be fatal in themselves, they do lead to
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deterioration and progressive symptoms, which for
MS consists of fluctuations of periods of long stability
punctuated by crises, while for PD this is marked by
a mixture of motor and non motor symptoms with
functional consequences underpinning the advanced
PD state. There are at any time 5,000 people with
MND, 120,000 with PD, 3,000 with MSA, 4,000-10,000
with PSP, and 100,000 with MS in the UK [17].
There are several potential barriers, next to the un-
predictable prognosis without a clear referral cut-off
point, to integration between specialist palliative care
and neurology. On the one hand, specialist palliative
care experts have been found to be reluctant to take on
care for non-cancer patients, due to a lack of disease-
specific knowledge [17]. On the other hand, neurologists
might not refer patients as they might not always see a
role for palliative care in their (complex) patients, associ-
ate palliative care with death and dying [18], or are
afraid to diminish patients’ hope by introducing palliative
care [19]. Last, it could be that patients themselves
might be reluctant to accept a referral, for reasons such
as the association of palliative care with end-of-life care
or longstanding relations with neurological services and
service providers. These barriers are important to take
into account and to address when developing potential
models of integrated care.
Various models could explore how neurology and
palliative care can complement each other so that pa-
tients may best benefit. For example, specialist pallia-
tive care could be used as an ‘add-on’ approach used
in time of need. Palliative care would then be pro-
vided in addition to neurology care, without taking
over. It would also imply that palliative care is provided
based on need rather than on prognosis or disease
stage. This reflects a shifting trend and is supported by
research showing that Parkinsonism patients’ symptoms
over time are better predicted by their initial level of
symptoms than by their disease stage [5]. Such models fit
also within the trend of a generalist and specialist pallia-
tive care approach [20], where neurology providers are
taught and expected to provide primary palliative care in
less complex situations. The America Stroke Association
has recently endorsed such an approach for stroke
patients [21]. While all providers caring for stroke patients
should be able to provide primary palliative care (e.g.,
develop appropriate goals of care), referral to specialist
palliative care should be done if necessary. While such
models seem plausible, we believe they should also be
rigorously tested before widely implemented.
We are currently in the process of testing such a new
model within some of the sites from this mapping exer-
cise. This exercise provided important contextual data to
develop this model in line with the preparation phase
of the MRC framework for developing and evaluating
complex interventions [22]. Incorporating this infor-
mation, our model builds further upon an earlier
study showing that an integrated approach improved
MS patients’ and caregivers’ outcomes, while decreas-
ing costs [13, 14]. However, whether similar effects
can be found across other diseases, managed in different
settings, with varied service provisions is unclear and
might become apparent from our own and future trials.
Potential factors to take into account when developing
and evaluating integrated models are disease groups,
co-terminus between neurology and specialist pallia-
tive care catchment areas and patients’ background
characteristics. Disease groups differ, as discussed, in
progression and survival. Next, the co-terminus
between neurology and palliative care services could
influence collaborations. If, as was the case for most
sites in our sample, neurology catchment areas exceed
palliative care catchment areas, neurology services
need to build relationships with different palliative
care teams, who might operate according to different
models and which might influence integration ap-
proaches. Last, patient characteristics could influence
needed care. For example, patients’ from ethnic mi-
nority groups have been found to suffer from more
aggressive MS trajectories compared to white British
patients [23] and are more inclined to attribute the
source of their illness to supernatural powers (e.g.,
fate) and less to biomedical factors (e.g., genetics)
[24]. They are also known to access palliative care at
disproportionally lower rates [25]. These and other
factors might vary between sites and might influence
the most appropriate provided services or integration.
This mapping exercise had limitations. Most import-
antly, as we asked clinicians to provide the detailed data
about not only their service provisions, but also the
number of patients they see and catchment area, issues
with the quality of the data emerged. Not all sites were
providing all information. One of the areas that often
lacked data was the population and square mileage fig-
ure. In these situations, the researchers tried to manu-
ally find them. In some cases we had to look up
additional information from websites or year reports.
This also served as a check for the quality of informa-
tion provided, although it was not feasible to check all
provided information. We were, however, impressed by
the willingness from both palliative care and neurology
providers to provide us with the needed information. A
final limitation of this exercise was that we focused on
neurology and palliative care provisions, but not on
rehabilitation care (both in specialist rehabilitation
centres and in the community; however in one site a
rehabilitation service was involved in ongoing support
of patients). This should be examined in the future, as
rehabilitation can play an important role in caring for
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neurology patients, for example, in symptom management
but also in the provision of equipment and coordination
of services [26]. Other settings, such as specialist care
homes, and disciplines, such as elderly care, might also
play a role and be relevant to explore.
Conclusions
Our findings show a variability in provided services and
integration between neurology and specialist palliative
care services, which varied not only between sites but
also between diseases. This variability indicates a lack of
knowledge informing which (integrated) models would
work best. Therefore, we hope our findings provide an
impetus for further work and development in this area
to ensure neurology patients’ palliative care needs are
met. New models of integrated care should be developed
and tested, taking into account differences in diseases,
co-terminus and demographic characteristics, with the
ultimate aim of improving provided care and patients’
and caregivers’ outcomes.
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